[Hormone replacement Up-to-date. Selective androgen receptor modulators (SARMs). Current status and their future].
Selective androgen receptor modulators (SARMs) with tissue or organ-specificity are expected for their development. Indeed, they will be widely applied for patients with late onset of hypodonadism and those with prostate cancer who have hormone treatment-induced osteoporosis. SARMs having anabolic action on the bone or muscle but no or weak androgenic action on the prostate will be welcomed in the clinical setting.
Tsukamoto
Taiji
T
Sapporo Medical University School of Medicine, Department of Urology, Japan.
Kato
Ryuichi
R
Kobayashi
Koh
K
D000368:Aged; D006801:Humans; D007006:Hypogonadism / Q000188:drug therapy*; D008297:Male; D011944:Receptors, Androgen / Q000187:drug effects*
D011944:Receptors, Androgen